Trevena (NASDAQ:TRVN) Receives New Coverage from Analysts at StockNews.com

Posted by Jeff Wilder on Oct 2nd, 2024

StockNews.com assumed coverage on shares of Trevena (NASDAQ:TRVN – Free Report) in a research note released on Sunday. The firm issued a sell rating on the biopharmaceutical company’s stock.

Trevena Price Performance

TRVN opened at $3.75 on Friday. The stock’s 50 day simple moving average is $3.23 and its 200 day simple moving average is $1.37. Trevena has a 1 year low of $3.35 and a 1 year high of $19.23. The firm has a market cap of $3.19 million, a price-to-earnings ratio of -1.36 and a beta of 1.03.

Trevena (NASDAQ:TRVN – Get Free Report) last issued its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.01) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.36. The business had revenue of $0.33 million during the quarter. As a group, sell-side analysts anticipate that Trevena will post -32.25 EPS for the current year.

Institutional Investors Weigh In On Trevena

An institutional investor recently bought a new position in Trevena stock. Armistice Capital LLC acquired a new stake in shares of Trevena, Inc. (NASDAQ:TRVN – Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 797,714 shares of the biopharmaceutical company’s stock, valued at approximately $576,000. Armistice Capital LLC owned about 4.61% of Trevena at the end of the most recent quarter. Hedge funds and other institutional investors own 13.56% of the company’s stock.

Trevena Company Profile

(Get Free Report)

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.